Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families
Japan-based Shionogi & Co. has entered into an option agreement with French firm Cilcare DEV SAS to acquire the exclusive license for the development, manufacturing, and commercialisation of CIL001 and/or CIL003, the hearing loss treatment drug candidates worldwide.
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Japan`s Shionogi says COVID treatment did not meet endpoint in late-stage trial
Maze lands new partner for Pompe drug, after Sanofi pact came apart
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
TOKYO, May 8, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2
The Global Health Innovative Technology (GHIT) Fund has announced an investment of Y1.64bn ($10.8m) in four new projects aimed at developing drugs to treat malaria and neglected tropical diseases (NTDs).
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections